Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ZLAB

ZLAB - Zai Lab Ltd Stock Price, Fair Value and News

$19.37-0.35 (-1.77%)
Market Closed

16/100

ZLAB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

16/100

ZLAB

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ZLAB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ZLAB Price Action

Last 7 days

-1.5%

Last 30 days

7.6%

Last 90 days

-0.9%

Trailing 12 Months

-41.6%

ZLAB RSI Chart

ZLAB Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ZLAB Valuation

Market Cap

21.8B

Price/Earnings (Trailing)

-105.45

Price/Sales (Trailing)

49.38

EV/EBITDA

-112.19

Price/Free Cashflow

-114.44

ZLAB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

ZLAB Fundamentals

ZLAB Revenue

Revenue (TTM)

441.6M

Rev. Growth (Yr)

13.52%

Rev. Growth (Qtr)

5.56%

ZLAB Earnings

Earnings (TTM)

-206.8M

Earnings Growth (Yr)

13.7%

Earnings Growth (Qtr)

11.7%

ZLAB Profitability

Operating Margin

75.52%

EBT Margin

-46.83%

Return on Equity

-27.21%

Return on Assets

-17.84%

Free Cashflow Yield

-0.87%

ZLAB Investor Care

Shares Dilution (1Y)

13.20%

Diluted EPS (TTM)

-0.19

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025418.3M427.8M441.6M0
2024291.1M322.7M355.7M399.0M
2023231.1M251.8M263.5M266.7M
2022170.9M182.2M196.6M215.0M
202160.8M86.8M115.2M144.3M
202020.9M28.8M38.5M49.0M
201900013.0M
20180000
Get all data in R, Python etc through our Historical Stock Data APIs

About Zai Lab Ltd

ZLAB
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Its commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. The company also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, it develops Zipalertinib for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; ZL-2313, an investigational oral EGFR inhibitor; ZL-1211, a humanized IgG1 monoclonal antibody that targets CLDN18.2; ZL-1218 is humanized IgG1 monoclonal antibody to induce potent antibody-dependent cellular cytotoxicity activity that enables NK cell-mediated killing of CCR8-expressing T-regs; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter; and KarXT for the treatment of psychiatric and neurological conditions. The company was incorporated in 2013 and is headquartered in Shanghai, China.
 CEO
 WEBSITEzailaboratory.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES2036

Zai Lab Ltd Frequently Asked Questions

ZLAB is the stock ticker symbol of Zai Lab Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Feb 23 2026, market cap of Zai Lab Ltd is 21.81 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Feb 23 2026, ZLAB's PE ratio (Price to Earnings) is -105.45 and Price to Sales (PS) ratio is 49.38. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ZLAB PE ratio will change depending on the future growth rate expectations of investors.